Shanghai Henlius Biotech Inc
HKEX:2696
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.7
23.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shanghai Henlius Biotech Inc
Total Liabilities & Equity
Shanghai Henlius Biotech Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Henlius Biotech Inc
HKEX:2696
|
Total Liabilities & Equity
¥9.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities & Equity
¥41.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities & Equity
¥15.7B
|
CAGR 3-Years
65%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Liabilities & Equity
¥32.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities & Equity
¥54.8B
|
CAGR 3-Years
32%
|
CAGR 5-Years
43%
|
CAGR 10-Years
36%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Liabilities & Equity
¥6.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
Shanghai Henlius Biotech Inc
Glance View
Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,234 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.
See Also
What is Shanghai Henlius Biotech Inc's Total Liabilities & Equity?
Total Liabilities & Equity
9.9B
CNY
Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Total Liabilities & Equity amounts to 9.9B CNY.
What is Shanghai Henlius Biotech Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
26%
Over the last year, the Total Liabilities & Equity growth was 11%. The average annual Total Liabilities & Equity growth rates for Shanghai Henlius Biotech Inc have been 15% over the past three years , 26% over the past five years .
You don't have any saved screeners yet
